Skip to content
Triangle logo TriangleGet started
← Full study record

NCT04439253 · FLOW

Participant flow

Testing Crizotinib as a Potential Targeted Treatment in Cancers With ROS1 Genetic Changes (MATCH-Subprotocol G) · Source last updated 2026-04-29

Results reported by the registry submitting party. Population, time horizon, units and missing values must be read together.

groups
  1. description
    Patients receive crizotinib 250 mg PO BID on days 1-28. Cycles repeat every 28 days in the absence of disease progression or unacceptable toxicity. Crizotinib: Given PO
    id
    FG000
    title
    Treatment (Crizotinib)
periods
  1. drop Withdraws
    1. reasons
      1. group Id
        FG000
        num Subjects
        1
      type
      Adverse Event
    2. reasons
      1. group Id
        FG000
        num Subjects
        2
      type
      Disease progression
    3. reasons
      1. group Id
        FG000
        num Subjects
        1
      type
      Complicating disease
    milestones
    1. achievements
      1. group Id
        FG000
        num Subjects
        4
      comment
      All 4 patients enrolled were eligible and treated in the arm.
      type
      STARTED
    2. achievements
      1. group Id
        FG000
        num Subjects
        0
      comment
      Treatment continued until disease progression or intolerability.
      type
      COMPLETED
    3. achievements
      1. group Id
        FG000
        num Subjects
        4
      type
      NOT COMPLETED
    title
    Overall Study
pre Assignment Details
To be assigned to a specific MATCH subprotocol, patients needed to submit a tumor biopsy for molecular characterization and those with molecular variants addressed by treatments included in the trial entered corresponding MATCH subprotocol. For the subprotocol G, patients had to have an ROS1 translocations (other than patients with non-small cell lung cancer).
recruitment Details
Subprotocol G was activated on August 12, 2015. A total of 5 patients were assigned to this arm after screening, 2 from screening cohort and 3 from outside assay. Of the 5 patients, 4 patients were enrolled to arm G between August 2015, and September 2018.
Complete source fields
groups
  1. description
    Patients receive crizotinib 250 mg PO BID on days 1-28. Cycles repeat every 28 days in the absence of disease progression or unacceptable toxicity. Crizotinib: Given PO
    id
    FG000
    title
    Treatment (Crizotinib)
periods
  1. drop Withdraws
    1. reasons
      1. group Id
        FG000
        num Subjects
        1
      type
      Adverse Event
    2. reasons
      1. group Id
        FG000
        num Subjects
        2
      type
      Disease progression
    3. reasons
      1. group Id
        FG000
        num Subjects
        1
      type
      Complicating disease
    milestones
    1. achievements
      1. group Id
        FG000
        num Subjects
        4
      comment
      All 4 patients enrolled were eligible and treated in the arm.
      type
      STARTED
    2. achievements
      1. group Id
        FG000
        num Subjects
        0
      comment
      Treatment continued until disease progression or intolerability.
      type
      COMPLETED
    3. achievements
      1. group Id
        FG000
        num Subjects
        4
      type
      NOT COMPLETED
    title
    Overall Study
pre Assignment Details
To be assigned to a specific MATCH subprotocol, patients needed to submit a tumor biopsy for molecular characterization and those with molecular variants addressed by treatments included in the trial entered corresponding MATCH subprotocol. For the subprotocol G, patients had to have an ROS1 translocations (other than patients with non-small cell lung cancer).
recruitment Details
Subprotocol G was activated on August 12, 2015. A total of 5 patients were assigned to this arm after screening, 2 from screening cohort and 3 from outside assay. Of the 5 patients, 4 patients were enrolled to arm G between August 2015, and September 2018.

Download exact source JSON → · Snapshot ctgov-results-25a395029948b04d52b1253f

Preserved source evidence · Not medical advice